Loading…
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-76M | $-74M | $-62M | -110.2% | -19.1% | - |
| 2024 | $0M | $-66M | $-64M | $-69M | -91.7% | -33.4% | - |
| 2023 | $0M | $-52M | $-50M | $-37M | -55.7% | -96.6% | - |
| 2022 | $10M | $-45M | $-45M | $-44M | -63.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 10.39 | 0.35 | 0.23 | 0.19 |
| Operating Expense | 56.79 | 55.27 | 68.15 | 77.82 |
| Operating Income | -46.40 | -54.92 | -67.91 | -77.63 |
| EBITDA | -44.71 | -52.18 | -66.37 | -76.07 |
| EBIT | -46.40 | -54.92 | -67.91 | -77.63 |
| Pretax Income | -45.34 | -50.40 | -64.02 | -74.12 |
| Net Income | -45.34 | -50.39 | -64.02 | -74.12 |
| Net Income Common Stockholders | -45.34 | -50.39 | -64.02 | -74.12 |
| Total Expenses | 56.79 | 55.27 | 68.15 | 77.82 |
| Research And Development | 42.81 | 42.29 | 54.37 | 60.22 |
| Selling General And Administration | 13.98 | 12.98 | 13.78 | 17.60 |
| Normalized EBITDA | -44.71 | -52.18 | -66.37 | -76.07 |
| Normalized Income | -45.34 | -50.39 | -64.02 | -74.12 |
| Basic EPS | -1.60 | -0.94 | -0.86 | 0 |
| Diluted EPS | -1.60 | -0.94 | -0.86 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -45.34 | -50.39 | -64.02 | -74.12 |
| Reconciled Depreciation | 1.70 | 2.74 | 1.54 | 1.55 |
| Net Income From Continuing And Discontinued Operation | -45.34 | -50.39 | -64.02 | -74.12 |
| Total Operating Income As Reported | -46.40 | -54.92 | -67.91 | -77.63 |
| Diluted Average Shares | 28.42 | 53.61 | 74.26 | 0 |
| Basic Average Shares | 28.42 | 53.61 | 74.26 | 0 |
| Diluted NI Availto Com Stockholders | -45.34 | -50.39 | -64.02 | -74.12 |
| Minority Interests | 0.01 | 0.01 | 0 | 0.01 |
| Net Income Including Noncontrolling Interests | -45.34 | -50.40 | -64.02 | -74.12 |
| Net Income Continuous Operations | -45.34 | -50.40 | -64.02 | -74.12 |
| Other Income Expense | 1.06 | 4.52 | 3.89 | 3.50 |
| Other Non Operating Income Expenses | 1.06 | 4.52 | 3.89 | 3.50 |
| General And Administrative Expense | 13.98 | 12.98 | 13.78 | 17.60 |
| Other Gand A | 13.98 | 12.98 | 13.78 | 17.60 |
| Operating Revenue | 10.39 | 0.35 | 0.23 | 0.19 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| aTyr Pharma, Inc.this co. | ATYR | $75M | - | 1.11 | -110.2% | -0.11 |
| Aldeyra Therapeutics, Inc. | ALDX | $90M | - | 2.04 | -76.5% | -1.02 |
| MaxCyte, Inc. | MXCT | $87M | - | 0.51 | -26.0% | -0.06 |
| biote Corp. | BTMD | $83M | 3.00 | -1.16 | -53.7% | 4.32 |
| Gossamer Bio, Inc. | GOSS | $82M | - | -0.67 |
| 138.8% |
| -0.91 |
| Outset Medical, Inc. | OM | $77M | - | 0.60 | -64.3% | -0.14 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Peer Median | - | 3.00 | 0.50 | -59.0% | -0.41 | |